Skip to main content
. 2016 Dec 10;8(4):6341–6352. doi: 10.18632/oncotarget.13856

Figure 5. In vivo effects of cytarabine and melflufen.

Figure 5

Effect presented as percent of HLAABC positive AML-ps cells in blood (determined by FACS) on day 30 A., proportion of animals free of leukemia at end of experiment on day 104 B., change in mean body weight of remaining live animals C. and median Kaplan-Meier survival curve D. Error bars denote SD.